CTOs on the Move

Karuna Pharmaceuticals

www.karunapharma.com

 
Karuna Pharmaceuticals is a clinical-stage company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Karuna Pharmaceuticals raised $42M on 07/11/2018
Karuna Pharmaceuticals raised $42M on 08/02/2018
Karuna Pharmaceuticals raised $68M on 03/18/2019
Karuna Pharmaceuticals raised $250M on 03/01/2021

Similar Companies

Bioniche Pharma USA

Bioniche Pharma USA LLC is a Lake Forest, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioZone Laboratories Inc

BioZone Laboratories Inc is a Pittsburg, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metabolic Solutions Development

Metabolic Solutions Development Company, LLC (MSDC) discovers and develops novel molecular targets and new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised nearly $55 million in support of the development of its novel therapeutic drugs, MSDC-0160 and MSDC-0602, which selectively modulate mitochondrial control of to important cellular activities, such as carbohydrate, lipid, and amino acid metabolism, that are out of balance in patients with type 2 diabetes. Such imbalances may also play a role in other diseases of aging such as Alzheimer’s disease and Parkinson’s disease, as well certain genetic diseases such as polycystic kidney disease.

Connections Behavior Planning & Intervention

ABA Therapy for children with ASD, EBD, & developmental disabilities. We serve King County, WA including Kent, Renton, Seattle, Kirkland, Redmond, & more.

Ascentage Pharma

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company`s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.